» Articles » PMID: 12714503

RANTES (CCL5) Uses the Proteoglycan CD44 As an Auxiliary Receptor to Mediate Cellular Activation Signals and HIV-1 Enhancement

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2003 Apr 26
PMID 12714503
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

The CC-chemokine RANTES (regulated on activation normal T-cell expressed and secreted; CCL5) transduces multiple intracellular signals. Like all chemokines, it stimulates G protein-coupled receptor (GPCR) activity through interaction with its cognate chemokine receptor(s), but in addition also activates a GPCR-independent signaling pathway. Here, we show that the latter pathway is mediated by an interaction between RANTES and glycosaminoglycan chains of CD44. We provide evidence that this association, at both low, physiologically relevant, and higher, probably supraphysiologic concentrations of RANTES, induces the formation of a signaling complex composed of CD44, src kinases, and adapter molecules. This triggers the activation of the p44/42 mitogen-activated protein kinase (MAPK) pathway. By specifically reducing CD44 expression using RNA interference we were able to demonstrate that the p44/p42 MAPK activation by RANTES requires a high level of CD44 expression. As well as potently inhibiting the entry of CCR5 using HIV-1 strains, RANTES can enhance HIV-1 infectivity under certain experimental conditions. This enhancement process depends in part on the activation of p44/p42 MAPK. Here we show that silencing of CD44 in HeLa-CD4 cells prevents the activation of p44/p42 MAPK and leads to a substantial reduction in HIV-1 infectivity enhancement by RANTES.

Citing Articles

Heparan sulfate-dependent phase separation of CCL5 and its chemotactic activity.

Yu X, Duan G, Pei P, Chen L, Gu R, Hu W Elife. 2024; 13.

PMID: 38949655 PMC: 11216747. DOI: 10.7554/eLife.93871.


Chronic Voluntary Morphine Intake Is Associated with Changes in Brain Structures Involved in Drug Dependence in a Rat Model of Polydrug Use.

Quintanilla M, Morales P, Santapau D, Avila A, Ponce C, Berrios-Carcamo P Int J Mol Sci. 2023; 24(23).

PMID: 38069404 PMC: 10707256. DOI: 10.3390/ijms242317081.


CCL5 might be a prognostic biomarker and associated with immuno-therapeutic efficacy in cancers: A pan-cancer analysis.

Huang Y, Wu L, Sun Y, Li J, Mao N, Yang Y Heliyon. 2023; 9(7):e18215.

PMID: 37519664 PMC: 10375802. DOI: 10.1016/j.heliyon.2023.e18215.


Heterodimers Are an Integral Component of Chemokine Signaling Repertoire.

Kaffashi K, Dreau D, Nesmelova I Int J Mol Sci. 2023; 24(14).

PMID: 37511398 PMC: 10380872. DOI: 10.3390/ijms241411639.


The regulatory network of the chemokine CCL5 in colorectal cancer.

Zhang X, Zhang X, Wang Y, Fang Y, Li M, Liu X Ann Med. 2023; 55(1):2205168.

PMID: 37141250 PMC: 10161960. DOI: 10.1080/07853890.2023.2205168.